Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
1.830
-0.160 (-8.04%)
Mar 31, 2025, 1:11 PM EDT - Market open
Prime Medicine Revenue
In the year 2024, Prime Medicine had annual revenue of $2.98M. Prime Medicine had revenue of $2.18M in the quarter ending December 31, 2024.
Revenue (ttm)
$2.98M
Revenue Growth
n/a
P/S Ratio
79.12
Revenue / Employee
$13,939
Employees
214
Market Cap
233.62M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PRME News
- 13 days ago - Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 4 weeks ago - Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PRNewsWire
- 4 months ago - Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha
- 4 months ago - Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics - GlobeNewsWire
- 5 months ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress - GlobeNewsWire